Strides have been made in the treatment of pulmonary arterial hypertension and interstitial lung disease in patients with systemic sclerosis, with successful trials of combination therapies in pulmonary arterial hypertension and of new drugs that slow the decline of lung function in interstitial lung ...
SummaryNumerous drugs have been recommended for the treatment of systemic sclerosis, but without any significant effect on the fibrotic stage of this disorder. Because recombinant gamma-interferon (γ-IFN) is a potent and selective inhibitor of fibroblast proliferation and collagen production by human ...
An international perspective on the future of systemic sclerosis research The diagnosis, treatment and management of systemic sclerosis (SSc) remains challenging, owing to the complexity of this disease. In this Perspective, an international group of experts discuss the future of SSc research and how...
no cure can be offered. Patients with severe and life-threatening manifestations of autoimmune diseases, such asmultiple sclerosis(MS), systemic lupus erythemathosus (SLE) andrheumatoid arthritis(RA), may require long-term maintenanceimmunosuppressive treatmentsimilar to organallograftrecipients, with all...
Systemic sclerosis (SSc) can be divided into two main phenotypes: diffuse and limited variants. The terms diffuse and limited refer to the extent of skin involvement. Limited SSc is what was formerly known as the CREST (Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiec...
The assessment of disease activity in systemic sclerosis (SSc) is challenging owing to its heterogeneous manifestations across multiple organ systems, the variable rate of disease progression and regression, and the relative paucity of patients in early-phase therapeutic trials. Despite some recent succes...
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous SSc (dcSSc) and the use of organ-specific therapies, has improved, as evident from randomized clinical trials. Treatment...
7.6.3 Cutaneous sclerosis treatment There is no consensus on the use of low dosages of pred- nisone (≤ 15 mg/day) in edematous cutaneous SSc. The use of corticosteroids at low doses in this indication requires a good evaluation of the risk-to-benefit ratio, including the ...
et al. Cannabinoids for the treatment of rheumatic diseases — where do we stand? Nat. Rev. Rheumatol. 14, 488–498 (2018). CAS PubMed Google Scholar O’Reilly, S. Toll like receptors in systemic sclerosis: an emerging target. Immunol. Lett. 195, 2–8 (2018). PubMed Google Scholar...
Systemic sclerosis (SSc; scleroderma) is a complicated idiopathic connective tissue disease with seldom effective treatment. GUI-ZHI-FU-LING-WAN (GFW) is a classic Traditional Chinese Medicine (TCM) formula widely used for the treatment of SSc. However, the mechanism of how the GFW affects SSc ...